Oncimmune Holdings PLC Agreement for Portugal and Spain (2173V)
05 April 2019 - 5:01PM
UK Regulatory
TIDMONC
RNS Number : 2173V
Oncimmune Holdings PLC
05 April 2019
5 April 2019
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Oncimmune Announces EarlyCDT(R) -Lung Kit Distribution Agreement
for Portugal and Extends Agreement for Spain
Oncimmune Holdings plc (AIM: ONC.L), a leader in the
development, manufacture and commercialisation of personalised
immunodiagnostics for the screening, detection and care of cancer,
today announces that it has signed an exclusive agreement for the
distribution of its EarlyCDT-Lung test kit in Portugal with
Sabartech S.L. ("Sabartech"), its existing distributor in Spain.
The agreement includes a minimum sales commitment of GBP700,000
over 5 years.
Every year in Portugal approximately 5,300 new cases are
diagnosed and approximately 4,700 deaths occur from lung cancer.
Lung cancer is the largest cause of cancer-related deaths in
Portugal.
Oncimmune has also extended Sabartech's agreement in Spain from
three to five years, in light of the excellent progress made
including the recently secured agreement to sell EarlyCDT-Lung as a
screening test for the early detection of lung cancer through the
hospitals and clinics of the Quirónsalud group ("Quirónsalud"). The
extension adds a further GBP1.8 million of minimum sales
commitments over years 4 and 5.
Dr Adam M Hill, CEO of Oncimmune commented: "Portugal and Spain
are important European markets and Sabartech has made good progress
so far including selling EarlyCDT-Lung for screening through
Quirónsalud, the largest private hospital network in Spain.
Extending our relationship to include Portugal was a natural
progression and marks another step in the commercialisation of
EarlyCDT-Lung."
-Ends-
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Mike Seabrook
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5700
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and
commercialisation of cancer specific immunodiagnostics for the
screening, detection and care of cancer. Oncimmune also develops
precision medicine and patient stratification tools for leading
pharmaceutical multinationals in both immuno-oncology and
autoimmune disease. Oncimmune is working to change how cancer is
diagnosed and treated. Its patented technology detects evidence of
the body's natural response to cancer, enabling detection four
years or more before standard clinical diagnosis. Oncimmune's tests
facilitate clinical decision-making and are complementary to
diagnostic technologies, making them valuable additions to
established and new care pathways. Oncimmune partners with leading
developers and distributors to make our technology available
globally.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT-Lung and EarlyCDT-Liver. To date, over 155,000 tests have
been performed for patients worldwide and EarlyCDT-Lung is being
used in the largest-ever randomised trial for the early detection
of lung cancer using biomarkers, the National Health Service (NHS)
ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune,
headquartered at its laboratory facility in Nottingham, UK, has a
discovery research centre in Dortmund, Germany and a CLIA lab in
Kansas, US as well as offices in London, UK and Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRCKQDDDBKBNQK
(END) Dow Jones Newswires
April 05, 2019 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024